Schroders says a looming pharmaceutical patent cliff and scarce venture capital are creating a potentially major opportunity in UK biotech.
- Big Pharma faces $67 billion in projected patent-expiry revenue losses by 2029.
- The industry holds roughly $1.3 trillion in dry powder, likely fueling acquisitions of external innovation.
- The UK “golden triangle” of London, Oxford, and Cambridge remains a core global hub for drug discovery.
- Venture fundraising has collapsed, creating a funding vacuum that may pressure valuations and improve investor entry points.
The UK’s problem has long been financing scale. If that gap narrows, Britain could capture far more value from the science it already produces.
Dit artikel verder lezen?
Abonneer en krijg toegang tot Investment Officer Nederland:
- Exclusief voor professionele beleggers
- Altijd opzegbaar
- Onbeperkt toegang: web, app, nieuwsbrieven en events
Registreer gratis en krijg toegang tot Investment Officer België:
- Exclusief voor professionele beleggers
- Altijd opzegbaar
- Onbeperkt toegang: web, app, nieuwsbrieven en events
Registreren duurt minder dan 1 minuut.
Geen betaalgegevens vereist
